Bisulfan

Phase 2Small molecule

Bisulfan is one of 15 small molecule programs targeting Allogeneic Hematopoietic Cell Transplant. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Allogeneic Hematopoietic Cell TransplantActive, not recruiting

Allogeneic Hematopoietic Cell TransplantPhase 2

Active, not recruiting

Competition

Competitive Landscape

17 competitors in Allogeneic Hematopoietic Cell Transplant

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 2

3 2

Cellcept

Roche

Phase 2

2 3

Nipent

Pfizer

Phase 2

1 4

Prograf

VVeloxis Pharmaceuticals

Phase 2

4 5

Cytoxan

BBaxter Healthcare Corporation

Phase 2

3 6

Rayos

RRoxane Laboratories

Phase 2

2 7

Campath

GGenzyme, a Sanofi Company

Phase 2

2 8

Sarclisa

AAzienda U.S.L. 1 di Massa e Carrara

Phase 2

1 9

Mesnex

BBaxter Healthcare Corporation

Phase 2

1 10

Alkeran

AApotex Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 2Active, not recruiting

Allogeneic Hematopoietic Cell Transplant

NCT03663933

Clinical

Trials by Indication[1]

Allogeneic Hematopoietic Cell Transplant1 trial

Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03663933·71 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Bisulfan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bisulfan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bisulfan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Cancer Institute (NCI)

Bisulfan

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Allogeneic Hematopoietic Cell Transplant1 trial

References

Drug Info

Quick Facts

Related News